A New Pathway to Beta Cells

Innovative process could increase beta cell supply for type 1 diabetes research and encapsulated cell replacement products An important new technique to more rapidly convert human embryonic stem cells (hESCs) into cells similar to pancreatic beta cells was reported recently in Nature Biotechnology. In a study partially funded by JDRF, Dr. Timothy Kieffer of the […]

JDRF Partner ViaCyte to Immediately Initiate Type 1 Diabetes Clinical Trial

Updated Sept. 18, 2014 JDRF’s partner ViaCyte recently announced the U.S. Food and Drug Administration (FDA) is allowing them to move forward with a clinical trial of its innovative type 1 diabetes (T1D) encapsulated cell replacement therapy called VC-01™ product candidate. The company plans to immediately initiate the first ever clinical evaluation of a stem […]

Top 10 Advances in T1D Research

JDRF-supported progress in fiscal year 2014 JDRF sets ambitious goals for progress in type 1 diabetes (T1D) research each year because our supporters inspire us to aim higher. We invite you to read about the real impact our strategic plan is making and hope you are as inspired as we are as each of these […]

Specific Protein May Help Beta Cells Survive in Type 1 Diabetes

JDRF-funded researchers find therapeutic potential of MANF protein to reduce beta cell stress in type 1 diabetes. In the healthy pancreas of someone without type 1 diabetes (T1D), the hormone insulin (essential for turning food into energy) is produced, stored, and released in a normal “factory-like” process within pancreatic beta cells in response to glucose […]

Hope for kidney health in gout drug

PERL study will explore the potential of allopurinol to delay or halt kidney disease in people with type 1 diabetes. As we near the end of March, National Kidney Month, we find ourselves at the beginning stages of an exciting new clinical trial that could lead to better health for people with type 1 diabetes […]

Merck smart insulin project advancing into clinical trials

On May 6, 2014, Merck held an investor briefing and provided updates on various strategic initiatives, including its smart insulin project acquired in 2010 when it purchased SmartCells. SmartCells — a diabetes drug-development company that received early support from JDRF — was founded in 2003 by Todd Zion, Ph.D., an MIT chemical engineer who had […]

Redefining the Diagnosis of Type 1 Diabetes

Updated criteria could open new possibilities for intervention before symptoms appear JDRF is leading a pertinent discussion in the diabetes field about what defines a diagnosis of type 1 diabetes (T1D). At the 14th Annual Rachmiel Levine Diabetes and Obesity Symposium today, Richard Insel, M.D., JDRF’s chief scientific officer, reviewed evidence supporting the need to […]

Potential drugs for beta cell regeneration discovered

At the April 2014 JDRF-GNF (Genomics Institute of the Novartis Research Foundation) meeting, Dr. Byran Laffitte described how GNF has the potential to identify the first disease altering therapy for T1D. He presented preclinical evidence that GNF has identified the first highly effective low molecular weight regulators of beta cell proliferation. Overall, GNF has identified […]

Progress on ViaCyte’s novel encapsulated cell therapy

In February, JDRF announced it is providing additional milestone-based funding for the continued development of ViaCyte’s VC-01™ encapsulated cell therapy product candidate for the treatment of T1D. JDRF will fund up to $7 million to help ensure a rapid transition of the project into the clinical phase of development once ViaCyte’s investigational new drug application […]